Screening for AL Amyloidosis in Smoldering Multiple Myeloma

Recruiting in Palo Alto (17 mi)

+14 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Recruiting

Sponsor: Tufts Medical Center

No Placebo Group

Trial Summary

What is the purpose of this trial?

In this multicenter study, we will recruit 400 patients 40 years of age or older at 15 centers with a diagnosis of smoldering multiple myeloma (SMM), a group of patients for whom standard of care is observation not treatment. The main goal of this study is to screen for the diagnosis of light-chain amyloidosis (AL) before the onset of symptomatic disease and to develop a training set for a likelihood algorithm.

Research Team

Eligibility Criteria

Inclusion Criteria

I am 40 years old or older.

I have been diagnosed with Smoldering Multiple Myeloma.

My blood test shows an abnormal protein level.

Treatment Details

Who Is Running the Clinical Trial?

Tufts Medical Center

Lead Sponsor

Trials

264

Recruited

264,000+

Michael Dandorph

Tufts Medical Center

Chief Executive Officer since 2022

MBA

Helen Boucher

Tufts Medical Center

Chief Medical Officer since 2022

MD, FACP, FIDSA

National Cancer Institute (NCI)

Collaborator

Trials

14,080

Recruited

41,180,000+

Dr. Douglas R. Lowy

National Cancer Institute (NCI)

Chief Executive Officer since 2023

MD from New York University School of Medicine

Dr. Monica Bertagnolli

National Cancer Institute (NCI)

Chief Medical Officer since 2022

MD from Harvard Medical School